Glaucoma
Conditions
Keywords
Travatan Dosing Aid, compliance monitoring dispenser
Brief summary
The primary objective of this study is to determine the opinions of patients who are given the Travatan Compliance Monitoring Dispenser to use to dispense their Travatan glaucoma drops.
Detailed description
Patients enrolled in this study will use the new Travatan compliance monitoring dispenser for 6 weeks. Patients will be informed that some, but not all, patients' compliance will be monitored by the device. Patients are randomly assigned to one of three groups (proportionally in a 2/2/1 ratio): 1. Fully functional Travatan compliance monitor 2. Travatan compliance monitor with LCD display and alarms disabled, but compliance monitoring intact 3. Travatan compliance monitor with LCD display, alarms and compliance monitor disabled. At end of study, patients fill out questionnaire assessing 1. Patient opinion regarding device: ease of use of new device; preference vs Travatan use without device, etc 2. patient's belief as to whether their compliance was monitored or not Rates of adherence are compared across groups and with regard to patients' reported beliefs as to whether they were monitored. The design of this study should allow the clinicians to ethically monitor compliance in patients who do and do not believe that they are being monitored. The use of monitoring devices without a functioning display and alarm should lead to some patients believing that they are not being monitored. As patients are told at the outset that they may or may not be monitored, this should be an ethically acceptable design. However, the collected data will allow a preliminary assessment of the impact of the patients' beliefs as to whether they are being monitored on their actual compliance, and hence an additional potential value of the device.
Interventions
Pt received fully functional monitoring dispenser for use with their Travatan eye drops
Patient received a particually functional Travatan Compliance Monitoring Dispenser
Patient received a non functioning Travatan Compliance Monitoring Dispenser
Sponsors
Study design
Eligibility
Inclusion criteria
* Open angle glaucoma or ocular hypertension * Presently using Travatan eye drops
Exclusion criteria
* Allergy to prostaglandin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assess patients' opinions regarding new Travatan Compliance Monitoring Dispenser | 6 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Pilot study of the impact of physician monitoring of compliance on patient compliance | 6 weeks |